Inolife Enters Into Gonadotropin Kinetics Research With Sanzyme

Press Release ( - TORONTO - Jun 04, 2018 - Inolife R&D Inc. (“Inolife”), an emerging life science company and an innovation leader in needle-free injection technologies, today announced that it has entered into an agreement with India-based pharmaceutical manufacturer Sanzyme Private Limited (“Sanzyme”).

Under the terms of the agreement, Inolife will provide Sanzyme with its Inojex needle-free injection technology, allowing Sanzyme to study the Pharmacokinetic profile and evaluate Bio-equivalence of Gonadotropin when delivered by way of needle-free injections. The Human Chorionic Gonadotropin (HCG) market is expected to reach $533M USD by 2022.

Sanzyme currently markets the following Gonadotropin products in pre-filled syringes (PFS):

  1. Endogen PFS – Highly purified FSH 75/150 IU Follicle Stimulating Hormone
  2. Gynogen PFS – Highly purified HMG 75/150 IU Human Menopausal Gonadotropin
  3. Pubergen PFS – Highly purified HCG 5000 IU Human Chorionic Gonadotropin

This relationship is perfectly aligned with Inolife’s development and distribution strategy, and is a clear expression of the company’s desire to take a strong stand in the life science sector.

Michael Wright

President & CEO


Using Inolife’s needle-free technology, Sanzyme will conduct the following studies:

  1. Single dose Pharmacokinetic study to evaluate Bio-equivalence of PK parameters (Cmax, Tmax, AUC. Plasma half-life) of Needle-free injector (NFI) Gonadotropin versus PFS Gonadotropin in healthy Female volunteers.
  2. Based on the results of PK study a phase III study to evaluate the Safety and Efficacy (non-inferiority) of the NFI Gonadotropin as compared to PFS Gonadotropin, where the typical sample size would be 100 plus.

Michael Wright, President & CEO of Inolife sees this as an important step in getting closer from having a huge positive impact on women affected by infertility. “Inolife is excited by the prospect of working with Sanzyme on a safer and pain-free delivery of Gonadotropin. We recognize the opportunities that this pharmaceutical partnership brings, and we are pleased to begin our relationship together.” Celebrating the important milestone reached, Inolife’s President & CEO further added that this relationship is perfectly aligned with Inolife’​s development and distribution strategy, and is a clear expression of the company’s desire to take a strong stand in the life science sector.

About Inolife R&D Inc. / Inolife Sciences Corporation
Inolife R&D Inc. is a life science company and an innovation leader in needle-free injection technologies. Inolife commercializes patented and FDA-cleared needle-free injection devices. The company was founded to take advantage of novel techniques of the liquid jet and ballistics-based epidermal drug injection that improve patients’ quality of life by making medicines easier to administer, work better, and remove the anxiety and inconvenience associated with hypodermic needle injections.

For more information about Inolife and its products, please visit

Michael Wright
President & CEO, Inolife R&D Inc.
Phone: 1 (866) 834-3777

About Sanzyme Private Ltd
Sanzyme is a leading pharmaceutical company in India engaged in the manufacturing and the marketing of pharmaceutical products under four segments namely hormones, male sexual health, probiotics and nephrology. It manufactures a wide range of products related to human healthcare. With the experience and respect it has gained over the last 42 years, Sanzyme operates two state of the art injectable and probiotic manufacturing facilities located in Hyderabad, India. It also operates Sanzyme Bio-Analytical Laboratory which provides quality and customer oriented in-vitro, in-vivo and preclinical toxicological services to the pharma and biotech industry.

For more information about Sanzyme and its products, please visit

Sanzyme Private Ltd
Phone: + 914048589999

Certain statements contained herein are “forward-looking” and are based on the opinions and estimates of management, or on opinions and estimates provided to and accepted by management. Forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those expressed or implied. Readers are therefore cautioned not to place reliance on any forward-looking statement.

Source : Inolife


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.